Cellino and Matricelf Partner for Global Expansion of Personalized Spinal Cord Injury Treatments
Cellino and Matricelf (TASE: MTLF) have announced a new collaboration aimed at accelerating the global biomanufacturing of personalized spinal cord injury treatments. This partnership leverages Cellino’s cutting-edge Nebula™ technology alongside Matricelf’s innovative regenerative approach. By combining Cellino’s automated induced pluripotent stem cell (iPSC) manufacturing capabilities with Matricelf’s double autologous 3D differentiation process, the collaboration seeks to pave the way for scalable, patient-specific regenerative therapies for spinal cord injuries.
Cellino and Matricelf have announced a transformative collaboration aimed at advancing personalized regenerative therapies for spinal cord injury. The partnership integrates Cellino’s proprietary Nebula™ biomanufacturing system with Matricelf’s advanced regenerative techniques, combining cutting-edge technology to address the urgent needs of spinal cord injury patients and accelerate the commercialization of life-changing therapies.
Cellino’s Nebula™ is a proprietary closed-cassette biomanufacturing system designed to produce high-quality induced pluripotent stem cells (iPSCs) at scale. The system ensures unparalleled consistency, sterility, and contamination-free production, which is critical for advancing regenerative medicine toward clinical application. Nebula™ makes on-demand iPSC production a reality, significantly enhancing the feasibility and scalability of patient-specific treatments.
As a significant milestone in their collaboration, Cellino successfully manufactured and delivered autologous iPSC lines from four donors to Matricelf. Matricelf, a biotech company specializing in regenerative therapies for spinal cord injury, integrates a unique approach that combines an extracellular matrix-based hydrogel derived from the patient’s own omentum. This hydrogel facilitates precise cell differentiation and tissue formation, eliminating the need for immunosuppression, a major barrier in traditional stem cell therapies.
Leveraging the iPSCs generated by Cellino, Matricelf has successfully differentiated them into functional neural tissues, demonstrating synchronized electrical activity—a hallmark of functional neural networks. The generated tissues underwent rigorous testing through industry-standard assays, which confirmed critical neural characteristics. These included genetic and protein markers specific to neural tissues, showing results comparable to Matricelf’s own iPSC-derived tissues, further validating the potential of this groundbreaking collaboration.
Looking ahead, Matricelf plans to file an Investigational New Drug (IND) application in the coming year to initiate clinical trials for their autologous iPSC-derived therapy. This step marks a significant milestone in developing regenerative treatments for spinal cord injuries, addressing an urgent and unmet need. The collaboration between Cellino and Matricelf is designed to restore function for millions of patients worldwide, significantly improving their quality of life.
“Collaboration on this international scale is a crucial step in realizing our vision of an entirely autologous regenerative therapy for spinal cord injury,” said Gil Hakim, CEO of Matricelf. “By combining Matricelf’s innovative platform with Cellino’s Nebula™ technology, we are setting new standards in scalable, patient-specific tissue engineering. This collaboration brings us one step closer to real-world applications of regenerative medicine.”
The ability to produce high-quality, patient-specific iPSCs at scale is expected to revolutionize regenerative medicine, making personalized treatments more accessible and effective. Marinna Madrid, Ph.D., Co-Founder and Chief Product Officer at Cellino, emphasized the importance of this collaboration, saying, “Our partnership with Matricelf exemplifies how international collaboration can accelerate innovation in regenerative therapies. It expands access to life-changing treatments, potentially transforming the future of spinal cord injury treatment.”
This partnership between Cellino and Matricelf represents the convergence of multiple advanced technologies—AI-driven automation, high-throughput biomanufacturing, and sophisticated neural tissue engineering. By leveraging these innovations, both companies are working to commercialize next-generation regenerative therapies for neurological diseases. The work being done today has the potential to radically change the landscape of spinal cord injury treatments, offering hope to millions of patients around the world.
In summary, this collaboration between Cellino and Matricelf brings together groundbreaking technologies to address the challenges faced in treating spinal cord injuries. By combining Cellino’s cutting-edge iPSC manufacturing system and Matricelf’s innovative tissue engineering approach, the partnership has set the stage for scalable, patient-specific regenerative therapies. With the IND application on the horizon, the future of spinal cord injury treatment is on the verge of a major breakthrough.
